This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Top Ranked Value Stocks to Buy for November 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 24th
Top Ranked Value Stocks to Buy for November 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 19th
Top Ranked Value Stocks to Buy for November 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 17th
Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma
by Zacks Equity Research
With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.
Innoviva (INVA) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.
AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has Innoviva (INVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (INVA) Outperforming Other Medical Stocks This Year?
Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session
by Zacks Equity Research
Innoviva (INVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Innoviva (INVA) Stock Moves -0.77%: What You Should Know
by Zacks Equity Research
Innoviva (INVA) closed at $14.13 in the latest trading session, marking a -0.77% move from the prior day.
Are Investors Undervaluing Innoviva (INVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Innoviva (INVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Innoviva (INVA) closed the most recent trading day at $13.92, moving +0.43% from the previous trading session.
Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study of Zeposia in patients with moderate-to-severe ulcerative colitis meets both its main goals.
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
Innoviva (INVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Innoviva (INVA) closed at $14.36 in the latest trading session, marking a -1.64% move from the prior day.
Are Investors Undervaluing Innoviva (INVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC
by Zacks Equity Research
The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.
Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INVA) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up
by Zacks Equity Research
As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.
Should Value Investors Buy Innoviva (INVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INVA) Outperforming Other Medical Stocks This Year?
New Strong Buy Stocks for May 1st
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
New Strong Buy Stocks for April 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: